Back to the complete issue
Sunday, 14 March 2021

GSK, Hikma end acquisition talks

Hikma Pharma won’t be acquiring GlaxoSmithKline’s Egypt unit: GSK and Hikma Pharma have agreed to end talks over a takeover bid submitted in January by the UK-listed company that would have seen it acquire a majority stake in GSK’s Egypt arm, both companies said (here and here – pdfs) on Thursday. Hikma will not go through with its mandatory tender offer for the British pharma giant’s distribution and manufacturing business in Egypt.

What happened? Neither Hikma nor GSK disclosed why the talks broke down. Neither company answered requests for comment.

Is there a fallback position: Acdima and Rameda both said they were interested in bidding for GSK’s local arm, but were slapped away by GSK last month.

Background: LSE-listed Hikma Pharma signed a non-binding agreement with GSK in late January to acquire its 91.2% stake in its Egypt and Tunisia units. Hikma appointed EFG Hermes as its financial advisor and Sharkawy & Sarhan as counsel in preparation for the potential acquisition.

Enterprise is a daily publication of Enterprise Ventures LLC, an Egyptian limited liability company (commercial register 83594), and a subsidiary of Inktank Communications. Summaries are intended for guidance only and are provided on an as-is basis; kindly refer to the source article in its original language prior to undertaking any action. Neither Enterprise Ventures nor its staff assume any responsibility or liability for the accuracy of the information contained in this publication, whether in the form of summaries or analysis. © 2021 Enterprise Ventures LLC.